Showing results (41-50 of 118) with videos related to
Sort By:
Pageof 12
Frontiers in Oncology|December 28, 2020
Radiomics Feature Activation Maps as a New Tool for Signature InterpretabilityDiem Vuong, Stephanie Tanadini-Lang, Ze Wu, et al.Plos One|September 17, 2013
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerFlorent Baty, Sacha Rothschild, Martin Früh, et al.Clinical Lung Cancer|May 29, 2012
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)Martin Früh, Richard Cathomas, Marco Siano, et al.BMJ Open|February 22, 2025
Estimating the indirect costs associated with adenocarcinoma or squamous cell carcinoma of the oesophagus in Switzerland: evidence from a cross-sectional surveySandro T Stoffel, Arjun Bhadhuri, Paola Salari, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2009
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial mannerLiat Izhak, Gizi Wildbaum, Uri Weinberg, et al.American Journal of Respiratory and Critical Care Medicine|October 17, 2009
Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancerFlorent Baty, Michaël Facompré, Sergio Kaiser, et al.Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review studyJacques Cadranel, Keunchil Park, Oscar Arrieta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter studyMiklos Pless, Karim Belhadj, Hans D Menssen, et al.Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|February 22, 2014
Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fieldsMoshe Giladi, Rosa S Schneiderman, Yaara Porat, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 1, 2025
Testing the effects of topical skin care products on Tumor Treating Fields (TTFields) adhesiveness of arrays and delivery of electric currentsMaya Sadovnik, Sewar Zbidat, Mariell Sellevoll, et al.Pageof 12